Article

CMS Extends Deadline to Appeal EHR Incentive Eligibility

Physicians and other so-called eligible professionals still wanting to appeal their eligibility determinations for the 2011 Medicare electronic health-record incentive payment program will have an extra month to file those appeals, the CMS announced.

The new deadline is April 30.

Read the full story: http://hcp.lv/HW1ouy

Source: ModernHealthcare

Related Videos
Sandra Cueller, PharmD
Ticiana Leal, MD
James Chambers, PhD
Mabel Mardones, MD.
1 KOL is featured in this series.
1 KOL is featured in this series.
Justin Oldham, MD, MS, an expert on IPF
Related Content
HIV | Image credit: RAJCREATIONZS - stock.adobe.com
November 15th 2024

BIC/FTC/TAF Effective at Virologic Suppression in HIV Presenting Late

Julia Bonavitacola
The combination therapy of bictegravir/emtricitabine/tenofovir (BIC/FTC/TAF) was both tolerable and produced virologic suppression in patients who were presenting late in their HIV infection.
Managed Care Cast
October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi
Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.
Woman squinting at phone | Image credit: Home-stock - stock.adobe.com
November 15th 2024

Postponed MacTel Treatment Approval Could Lead to Delay of Needed Care

Julia Bonavitacola
A delay in the FDA decision for NT-501 could leave those with macular telangiectasia (MacTel) without any form of treatment for longer than anticipated.
managed care cast logo
October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Gene therapy, gene editing concept | image credit: vchalup - stock.adobe.com
November 15th 2024

Delandistrogene Moxeparvovec Fails to Meet Primary End Point in Phase 3 Study

AJMC Contributor
Put up against placebo in the phase 3 EMBARK trial, delandistrogene moxeparvovec (Elevidys) did not significantly improve function after 52 weeks.
In the Press
November 15th 2024

AJMC® in the Press, November 15, 2024

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo